Compare ACADIA Pharmaceuticals Inc. (ACAD) vs First Trust NASDAQ Cybersecurity ETF (CIBR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs First Trust NASDAQ Cybersecurity ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while First Trust NASDAQ Cybersecurity ETF trades at $91.28. The key difference: First Trust NASDAQ Cybersecurity ETF is trading nearer its 52-week high, ACADIA Pharmaceuticals Inc. nearer its low. Which is the better fit depends on your goals.
| ACAD | CIBR | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | — |
52-Week High | $28.06 | $94.32 |
52-Week Low | $20.06 | $60.74 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
CIBR (First Trust NASDAQ Cybersecurity ETF) trades at $92.21, up 1.7% with strong bullish momentum. Technical indicators show moving averages in bullish alignment while oscillators signal neutral conditions. The ETF has significantly outperformed the S&P 500, gaining approximately 22% year-to-date through June 2026 versus 8% for the broader market. Recent news highlights growing cybersecurity spending exceeding $300 billion globally, with CIBR positioned as a clean play on AI-driven security demand.
The cybersecurity sector benefits from structural growth drivers including AI-powered threats and mandatory corporate spending. CIBR offers diversified exposure to 30+ cybersecurity companies with reasonable valuation at 24x P/E. Key risks include concentrated tech exposure and market volatility, but institutional buying and positive analyst sentiment support the bullish outlook for this thematic ETF.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About First Trust NASDAQ Cybersecurity ETF
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index includes securities of companies classified as cyber security companies. The fund is non-diversified.
Read more on CIBR →
